(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual revenue growth rate of 865.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.4%.
Nrx Pharmaceuticals's revenue in 2026 is $1,225,000.On average, 6 Wall Street analysts forecast NRXP's revenue for 2026 to be $1,072,581,647, with the lowest NRXP revenue forecast at $1,030,519,621, and the highest NRXP revenue forecast at $1,104,128,166. On average, 4 Wall Street analysts forecast NRXP's revenue for 2027 to be $18,145,200,610, with the lowest NRXP revenue forecast at $16,896,566,901, and the highest NRXP revenue forecast at $19,254,288,920.
In 2028, NRXP is forecast to generate $36,771,204,560 in revenue, with the lowest revenue forecast at $33,563,644,450 and the highest revenue forecast at $39,714,223,630.